LASALasa Supergenerics Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products in India. It offers API bulk drug products comprising fenbendazole, toldimphos sodium, cyromazine, albendazole, ricobendazole, triciabendazole, oxfendazole, closantel base, closantel sodium dihydrate BP, nitroxynil, rafoxanide, oxyclozanide, ornidazole, halquinol, and 2,6-diiodo-4-nitrophenol; and other API products. The company also provides animal feed ingredients, including calcium iodate; and reagents for therapeutic use, such as potassium iodide. In addition, it exports its products. Lasa Supergenerics Limited was incorporated in 2016 and is based in Ratnagiri, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
Why avoid
- • Overall evidence is weak (AlgoScore 20/100)
- • Revenue growth: -93.4% YoY
- • Profit growth: -131.0% YoY
- • RSI: 32
- • MACD: bearish
- • Double Top bearish signal (setup quality 57%)
Bull case
- • Debt/Equity: 0.20
- • Promoter holding: 54.6%
- • Trend strength (ADX): 31
- • Sector momentum: sector +6.2% (1m)
Bear case
- • Revenue growth: -93.4% YoY
- • Profit growth: -131.0% YoY
- • RSI: 32
- • MACD: bearish
Key risks
- • Elevated volatility / drawdown profile — size positions accordingly
- • Weak fundamentals — technical strength may not sustain
- • Momentum is fading versus the broader market
- • Revenue growth: -93.4% YoY
- • Profit growth: -131.0% YoY
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹0.38). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.